



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 65180

**Title:** Genetics of macrovascular complications in type 2 diabetes

**Reviewer's code:** 05865912

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** Russia

**Manuscript submission date:** 2021-03-01

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-04 20:42

**Reviewer performed review:** 2021-03-11 09:55

**Review time:** 6 Days and 13 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

I commend the authors for writing this review. It is an excellent review on the ever-emerging literature about genetics of macrovascular complications in T2D. 1. In my opinion could be more elegant to change for all the text T2D with T2DM. Please correct it. 2. If authors can include the management of these complications in T2DM, it will be great. 3. Regards the ACE2 receptors, their expression and clinical outcomes, do not forget to report that hypertension is more common than T2DM in patients with COVID-19 infection (Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. *Journal of Clinical Medicine* 2020; doi: 10.3390/jcm9051417). Indeed, a particular interest has been invested on the expression of ACE2 receptors and on clinical outcomes in hypertensive patients, and in hypertensive patients under ACEi/ARBs drugs. Indeed, hypertensive patients represent a class of high risk patients (Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy. *J Am Heart Assoc.* 2020 Jul 7:e016948. doi: 10.1161/JAHA.120.016948). Notably, there is not actual evidence to discontinue this chronic therapy in hypertensive patients with COVID-19 infection. Please discuss this point, to remark a brief description of hypertensive patients and antihypertensive drugs in COVID-19 disease. 4. Please revise the English of the manuscript, there are little bit problems.